Denied the petition. Not the outcome.

A reclassification petition gets denied, and the easy reading is that the product code stays put. For product code OAY — diagnostic endoscopic light source systems, Class III, premarket approval required under 21 CFR Part 876 — that reading lasted about five months.

What the denial actually said

Per the sponsor’s own public regulatory disclosures, FDA told Photocure ASA in late March 2026 that it would not grant the pending petition to reclassify OAY equipment into Class II: the agency wanted more clinical evidence and a more robust set of special controls before it would accept a 510(k) framework in place of PMA review. FDA’s stated objection, per that same disclosure, wasn’t to the underlying technology — blue-light cystoscopy systems used with an approved optical imaging agent to help detect bladder cancer — it was to the specific record the petition had built. A denial on that ground answers “not on this record,” not “not ever.” The same disclosure said FDA had signaled it intended to issue its own proposed order on the same question later in 2026.

The order FDA filed itself

On August 17, 2026, FDA published that order — not a reclassification granted on the denied petition, but a new proposed order under section 513(f)(3) of the FD&C Act, the provision built for exactly this situation: reclassifying a device that landed in Class III automatically, the way most postamendments devices found substantially equivalent to a preamendments Class III predicate do, rather than one Class III assignment a panel chose device-by-device. The proposed order would move product code OAY from Class III into Class II, subject to 510(k) premarket notification instead of PMA. A petition’s denial and an agency’s own motion run on different legal tracks inside the same statute, and nothing in 513(f)(3) requires the second to wait on, or follow from, how the first one came out.

Two classification actions, one notice

The same notice does more than move an existing code. It also proposes an entirely new classification regulation — “Cystoscopic system intended as an aid for detection of bladder cancer” — for systems used with an approved optical imaging agent, as an adjunct to standard white-light cystoscopy, to detect known or suspected bladder cancer, including carcinoma in situ, and for surveillance after treatment. The special controls FDA proposes name the risks the new type is built around: false positive and false negative results, device failure or malfunction, electrical, thermal, or light injury, interference with other devices, infection or cross-contamination, and adverse tissue reaction. Reclassifying OAY and creating this new type are two separate exercises of FDA’s classification authority, bundled into one docket because the hardware and the narrower diagnostic use case overlap — not because they are the same decision.

A proposed order is FDA’s classification authority in motion, not its destination. Product code OAY is Class III today, under the regulation on the books today, and stays that way until a final order says otherwise.

The practice

Reading this correctly takes tracking two things the Federal Register feed carries, not one: the proposed order itself, and whatever final order eventually closes it — on its own timeline, possibly with changes from what was proposed in August. A denied petition from the spring told a reader nothing reliable about where the fall would land. A device company watching product code OAY, or weighing whether its own device might fit the new cystoscopic-system type once it exists, is watching a proposal, not a rule, and the gap between the two is exactly where premature conclusions get made. This is regulatory intelligence and method, never regulatory advice about how this specific proceeding will resolve, or what classification a specific device would fall under if it does — those are determinations for your regulatory professional, built on the final order whenever FDA issues one.